Key Laboratory for Tumor Precision Medicine of Shaanxi Province and Department of Endocrinology , The First Affiliated Hospital of Xi'an Jiaotong University , Xi'an 710061 , China.
Frontier Institute of Science and Technology, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology , Xi'an Jiaotong University , Xi'an 710049 , China.
Nano Lett. 2019 Dec 11;19(12):8708-8715. doi: 10.1021/acs.nanolett.9b03414. Epub 2019 Nov 25.
Immune checkpoint blockade therapies fail to induce immune response in the vast majority of cancer patients, so developing robust adjuvants for increasing tumor immune response is central for effective tumor immunotherapy. The Wnt/β-catenin pathway is a crucial oncogenic signal in relation to tumor immune evasion; however, none of the Wnt inhibitor under clinical or preclinical phases has demonstrated satisfactory specificity. Thus, new compounds or modalities that tumor specifically modulate the Wnt signal will be of great significance and value in clinical tumor immunotherapy. Herein, inspired by a natural phenomenon in cancer cells that the Achilles' Heel of oncoprotein β-catenin, H1 helix, predisposes β-catenin to oligomerization for proteasomal degradation and can be exacerbated by carnosic acid (CA, a Wnt inhibitor), we developed a size-tuned nanocluster (CA) with well-defined supramolecular nanostructure by coassembling CA and H1 peptide. With the inherent enhanced permeability and retention (EPR) effect and the designed tumor microenvironment (TME) responsiveness, the CA tumor specifically suppress the Wnt/β-catenin cascade , while maintaining a highly favorable biosafety profile. More importantly, the CA improved the tumor response to the PD1/PD-L1 immune checkpoint blockade in melanoma and colon cancer. This study provides new insights into the biomimetic coassembly strategy to design supramolecular nanostructured adjuvants for hazard-free Wnt suppression and synergy with tumor immunotherapy.
免疫检查点阻断疗法未能在绝大多数癌症患者中诱导免疫反应,因此开发有效的肿瘤免疫疗法来增强肿瘤免疫反应的佐剂是至关重要的。Wnt/β-catenin 途径是与肿瘤免疫逃逸相关的关键致癌信号;然而,在临床或临床前阶段的没有一种 Wnt 抑制剂表现出令人满意的特异性。因此,能够特异性调节 Wnt 信号的新化合物或模式在临床肿瘤免疫治疗中将具有重要意义和价值。在此,受癌细胞中一种自然现象的启发,即癌蛋白β-catenin 的阿喀琉斯之踵 H1 螺旋易于导致β-catenin 寡聚化并通过 Carnosic 酸 (CA,一种 Wnt 抑制剂) 进行蛋白酶体降解,我们通过共组装 CA 和 H1 肽开发了一种具有明确定义的超分子纳米结构的尺寸可调纳米簇 (CA)。由于具有内在的增强渗透和保留 (EPR) 效应和设计的肿瘤微环境 (TME) 反应性,CA 可特异性抑制肿瘤中的 Wnt/β-catenin 级联,同时保持高度有利的生物安全性。更重要的是,CA 提高了黑色素瘤和结肠癌对 PD1/PD-L1 免疫检查点阻断的肿瘤反应。本研究为设计无危险的 Wnt 抑制和与肿瘤免疫治疗协同作用的仿生共组装策略提供了新的见解。